Apollo Hospitals Enterprise Limited
Momentum (86/100) does the heavy lifting; valuation (6/100) is the drag.
ExpensiveOvervaluedApollo Hospitals Enterprise Limited earns a Hold from StocksWizard, with a blended score of 45/100. We put fair value near ₹5,046.5; at ₹8,957 that leaves roughly 44% downside, so the stock screens overvalued by 44%. On 63.5x trailing earnings it sits pricier than the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹8,988. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹9,208.2 implies about 3% upside across 30 analysts. It clears 7 of 13 investability checks, with durability 54, valuation 12 and momentum 86 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹4,037.2.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-0.34% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 21.5%
- Fail: Low debt (D/E < 0.5): 0.85x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 18%
- Pass: Earnings growing: 36%
- Fail: Net margin ≥ 10%: 7.7%
- Fail: Current ratio > 1.5: 1.06
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 7.46
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter28.0%
- Institutions51.3%
- Public & other20.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (21.5%).
- Trading near its 52-week high.
- Financially solid — Altman Z 7.46.
Opportunities
- Earnings growing (36% YoY).
- Revenue growing (18% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~44% above our estimated fair value.
About Apollo Hospitals Enterprise Limited
Apollo Hospitals Enterprise operates a network of healthcare facilities across India offering primary, secondary, tertiary, and specialty care services. The company generates revenue through four business segments: Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and other operations. Its subsidiaries support the broader healthcare platform.
Apollo Hospitals Enterprise Limited — frequently asked questions
Is Apollo Hospitals Enterprise Limited a buy, hold or sell?
StocksWizard currently rates Apollo Hospitals Enterprise Limited (APOLLOHOSP) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Apollo Hospitals Enterprise Limited's fair value?
Our blended DCF and relative-valuation model estimates Apollo Hospitals Enterprise Limited's fair value at about ₹5,046.5, versus a current price of ₹8,957 — roughly 44% downside. On that basis the stock looks overvalued by 44%.
Is Apollo Hospitals Enterprise Limited financially healthy?
Apollo Hospitals Enterprise Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Apollo Hospitals Enterprise Limited's share price performed?
Apollo Hospitals Enterprise Limited is up 15% over three months, and last traded at ₹8,957. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.